Fusion Antibodies (LSE:FAB) Other Long-Term Liabilities : £0.02 Mil (As of Sep. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Fusion Antibodies Other Long-Term Liabilities?

Fusion Antibodies's other long-term liabilities for the quarter that ended in Sep. 2023 was £0.02 Mil.

Fusion Antibodies's quarterly other long-term liabilities declined from Sep. 2022 (£0.02 Mil) to Mar. 2023 (£0.02 Mil) and declined from Mar. 2023 (£0.02 Mil) to Sep. 2023 (£0.02 Mil).

Fusion Antibodies's annual other long-term liabilities increased from Mar. 2021 (£0.02 Mil) to Mar. 2022 (£0.02 Mil) but then declined from Mar. 2022 (£0.02 Mil) to Mar. 2023 (£0.02 Mil).

Fusion Antibodies Other Long-Term Liabilities Historical Data

The historical data trend for Fusion Antibodies's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fusion Antibodies Other Long-Term Liabilities Chart

Fusion Antibodies Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Other Long-Term Liabilities

Get a 7-Day Free Trial

Fusion Antibodies Semi-Annual Data
	Mar15	Mar16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Other Long-Term Liabilities	Get a 7-Day Free Trial											-	-	-	-	-

Fusion Antibodies Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Fusion Antibodies Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Fusion Antibodies's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Fusion Antibodies (LSE:FAB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fusion Antibodies PLC (LSE:FAB) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Springbank Road, Springbank Industrial Estate, Dunmurry, Belfast, GBR, BT17 0QL

Website

https://www.fusionantibodies.com

Fusion Antibodies PLC offers a range of antibody engineering services for all stages of therapeutic and diagnostic antibody development. It is engaged in the research, development, and manufacturing of recombinant proteins, particularly in the areas of cancer and infectious diseases. Its services include antibody sequencing, antibody humanization, stable cell line development, monoclonal antibody production, and transient protein expression. Geographically company generates the majority of its revenue from North America.

Fusion Antibodies (LSE:FAB) Headlines

From GuruFocus

626 Financial, LLC Buys 3, Sells 2 in 3rd Quarter

By GuruFocus Research GuruFocus Editor • 10-21-2022